作者: Xu, Shan ; Jiang, Qihua ; Chen, Xiaoying ; Kang, Shengnan ; Hao, Lan ; Liu, Xian ; Huang, Wenxiang ; Liu, Jinglun ; Zhang, Shu ; Zhang, Dan ; Ran, Haitao

Purpose: To investigate the synergistic effect of bovine cateslytin-loaded nanoparticles (bCAT-NPs) combined with ultrasound against Candida albicans biofilm and uncover the underlying mechanism. Methods: bCAT-NPs were prepared by the double emulsion method, and toxicity was observed by the hemolysis ratio. The metabolic activity and viable cell biomass, morphology and membrane permeability of C. albicans biofilm were observed. The expression of ALS3 mRNA, the content of reactive oxygen species, was detected. Finally, bCAT structure was analyzed. Results & conclusion: The hemolysis ratio of the bCAT-NPs group was significantly lower than that of the bCAT group. bCAT-NPs combined with ultrasound significantly reduced biofilm metabolic activity, inhibited the formation of hyphae, decreased the expression of ALS3 mRNA and increased the intracellular reactive oxygen species content. In the in vivo experiments, the colony-forming units/ml in the ultrasound+bCAT-NPs group decreased, and a few planktonic fungal cells were observed.

2022-01-01·Nature reviews. Drug discovery

Novo Nordisk and GlaxoSmithKline buy into RNAi

作者: Mullard, Asher

A review.Dicerna has six candidates in the clinic, for liver, cardiometabolic and HCV indications.Nclisiran, discovered by Alnylam, is currently under FDA review.

2021-11-01·Therapeutic delivery

Industry News Update Covering July 2021

Article

作者: Timmins, Peter

Quite a number of news items this month included cell/gene therapy and RNA/oligonucleotide therapeutics stories.These included a new gene therapy becoming available from bluebird bio, as well as the return to the market of a product from that company after it had been voluntarily suspended to allow for a suspected safety issue to be resolved.Others had less pos. news, like Adverum which unfortunately had to terminate trials of its ophthalmic disease gene therapy due to serious safety concerns.RNA-based therapeutics included Dicerna's new antisense for rare liver disease and Arrowhead's gene silencing agent for kidney cancer showed favorable Phase I trial outcomes.However, Arrowhead's cystic fibrosis RNA interference drug had preclin. safety concerns that paused an early phase trial.Bicycle Therapeutics and Ionis Pharmaceuticals agreed a collaboration to develop tissue-specific oligonucleotide therapeutics using cyclic peptide targeting while Moderna moved its mRNA vaccine technol. on from COVID-19 to explore a multivalent influenza vaccine.Still in large mol. space, some interesting biologics-enabling technologies were announced with Lilly accessing glucose-sensing insulin approaches, VitriVax gaining funding to advance its thermostable vaccine technol. and Prime Medicine taking a novel gene editing approach forward with its combined fusion protein editor/RNA guide and replacer template complex delivered via a lentivirus vector technol.Small mols. also were still bringing therapeutic advances, either well-known mols. through drug delivery technol. into new indications (e.g., budesonide-targeted modified release capsule from Stada/Calliditas) or with novel mols. against novel targets (e.g., Ribon's PARP7 inhibitor).Drug delivery technol. companies were the target of acquisitions, perhaps most significantly with cigarette maker Philip Morris stepping into the delivery technol. space in buying Fertin Pharma and bidding to acquire Vectura.

项与 CTNNB1 DsiRNA 相关的新闻（医药）

2024-01-03

·Firstwordpharma

Boehringer returns to RNA for NASH in $2B deal with Ribo

It’s been just over six years since Boehringer signed a pair of deals to develop RNA-based therapeutics to treat non-alcoholic steatohepatitis (NASH), neither of which have resulted thus far in a clinical candidate. Now the pharma is revisiting the modality and disease match-up, thanks to a partnership announced Wednesday with Suzhou Ribo Life Science that’s potentially worth more than $2 billion in biobucks. As part of the collaboration, which comprises multiple targets, the China-based biotech will use its small interfering RNA (siRNA) liver-targeting delivery technology, dubbed RIBO-GalSTA, to develop candidates. Ribo received an undisclosed upfront payment, and is eligible for clinical, regulatory, and commercial milestones, plus tiered royalties, for an overall deal value greater than $2 billion. No drug has yet been approved to treat NASH. While a series of pipeline failures have plagued the space, antisense oligonucleotide and RNA treatments are showing promise. For more, see Spotlight On: Mapping a recovering NASH landscape.Boehringer’s NASH past Boehringer first explored RNAi’s potential to treat NASH through November 2017 partnerships with MiNA Therapeutics and Dicerna Pharmaceuticals. Both agreements had much smaller sticker prices than Wednesday’s deal with Ribo. The MiNA deal was valued at over €300 million; Dicerna was eligible to receive over $200 million between an upfront payment and milestones. While Boehringer hasn’t given an update on its collaboration with MiNA, the drugmaker did select to develop an RNAi candidate from Dicerna in 2021. According to ClinicalTrials.gov, the compound, dubbed DCR-LIV2, has not yet entered clinical trials.Boehringer’s current pipeline has one candidate in the clinic for NASH: Survodutide (BI 456906), a dual GLP1/GCGR agonist in-licensed from Zealand Pharma in 2011. The treatment is in Phase II testing for both NASH and obesity. RNA frontrunners At least two RNAi therapeutics have already reached Phase II testing for NASH: ALN-HSD from Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, and GSK4532990 (ARO-HSD) from GSK and Arrowhead Pharmaceuticals.GSK kicked off a Phase IIb trial in April 2023, for which Arrowhead received a $30 million milestone payment. Alnylam and Regeneron began recruiting patients for their Phase II trial in February 2023, following promising Phase I results showing robust target knockdown and lower liver enzymes.

临床2期引进/卖出临床1期寡核苷酸

100 项与 CTNNB1 DsiRNA 相关的药物交易

登录后查看更多信息